Accueil   Diary - News   All news Theranexus obtains the authorization to start a phase 1b clinical trial

Theranexus obtains the authorization to start a phase 1b clinical trial

 

Theranexus obtains the authorization to start a phase 1b clinical trial with its drug candidate THN201 in neurocognitive disorders due tu Alzheimer's disease

 

Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells, announces today it received the approval from French regulatory authorities to start a Phase Ib clinical trial with its drug candidate THN201.



Read the press release